Religare Enterprises Ltd Q3 FY2026 Concall Summary & Transcript Notes

Source transcript PDF: https://www.stockscans.in/document/uhrk9afbftyzb4b386qy2sn2.pdf

# 1. Financial Performance

## A. Key Figures
   * **Total Consolidated Income:** **₹2,067.9 Cr** (QoQ) (+24% YoY) · **₹6,033.1 Cr** (9M) (+12.6% YoY)
   * **Net Loss:** **₹5.93 Cr** (Q, IFRS)
   * Solvency Ratio: 1.70 (Q3)
   *   **ROE:** **Mid-teens** (3-year average)

## B. Revenue Growth
   *   **Strong Underlying Growth:** Robust top-line expansion driven by healthy franchise momentum and rising policy volumes, despite significant deferral of revenue recognition under 1/n accounting.
   *   **Accounting Impact:** Full premium basis shows profitability and growth continuity since FY19, while 1/n and IFRS-based results reflect timing differences from long-term policy deferrals, not economic loss.
   *   **Revenue Volatility:** Sharp YoY quarterly revenue decline in one segment due to reduced book size, though offset by lower expenses and digital efficiency gains.

## C. Profitability Trends
   *   **Core Profitability Resilient:** PBT surged on full premium basis with **23% YoY underwriting improvement**, accelerating to **27% after excluding one-time labor code impact**.
   *   **One-Time Pressures:** IFRS net loss driven by **impairment provision of ₹21 Cr** and **one-time labor code cost of ₹5 Cr**, both non-recurring in nature.
   *   **Efficiency Gains:** Combined ratio improved **110 bps YTD** amid declining expense of management, supported by scale and digital adoption.
   *   **Rating Upgrade Achieved:** Profitability sustainability recognized with credit rating uplift from **A+ to AA-**, reinforcing balance sheet strength.

---

# 2. Loan Book & Asset Quality

## A. Key Figures
   *   **SME AUM:** **₹70 Cr** (core book) · **₹70 Cr** (remaining good book)
   *   **Net NPA Ratio:** **1%** (stable)
   * CRAR: 228% (Religare Finvest) · 132% (Religare Housing Finance)

## B. SME Portfolio Performance
   *   **High-Quality Core Book:** SME portfolio remains concentrated and high-performing, with **near-total collection efficiency** reflecting disciplined underwriting and recovery focus.
   *   **Liquidity Cushion:** Cash balance exceeds **₹500 Cr**, providing ample runway and financial flexibility amid ongoing resolution of legacy assets.
   *   **Legacy Risk Overhang:** Multiple bad loans in litigation phase; recoveries dependent on judicial outcomes, creating uncertainty on timing of inflows.

## C. NPA & Provisioning Status
   *   **Stable Asset Quality:** Net NPAs contained at minimal levels, supported by rigorous monitoring and proactive provisioning across non-performing corporate loans.
   *   **Capital Strength:** CRAR remains well above regulatory requirements, underscoring robust capital adequacy and resilience post-clean-up.
   *   **Active Recovery Framework:** Dedicated collection team in place, pursuing litigation-led recoveries with improved collections quarter-on-quarter.

---

# 3. Capital & Funding Structure

## A. Key Figures
   *   **Net Worth:** **₹800 Cr** RFL (post-LVB provision) · **₹2,000 Cr** group-level estimate · **₹366 Cr** Religare Broking
   * Solvency Target: 1.7 or above post-infusion
   *   **CRAR:** **132%** (down from 142%)

## B. Net Worth & Solvency
   *   **Resilient Capital Base:** RFL’s net worth of ₹800 Cr reflects full provisioning for LVB’s ₹750 Cr FD, underscoring conservative risk management and balance sheet integrity.
   *   **Strategic Capital Priorities:** Focus on risk-adjusted returns, governance strengthening, and long-term value compounding underpins capital allocation discipline.
   *   **Ownership & Structure:** Post-warrant conversion, REL promoter group will hold **75%**, with public at **25%**; REL listed (BSE/NSE), RFL unlisted but RBI-registered NBFC.
   *   **Book Value Visibility:** Demerged business book value estimated at **₹70–90 per share** post write-offs, providing anchor for intrinsic value assessment.

## C. Capital Infusion Use
   *   **Targeted Deployment:** Capital allocation remains selective, with ₹256 Cr infused into CARE Health Insurance and remaining funds directed to broking, housing finance, and REL operations.
   *   **Future Funding Pipeline:** ~**₹900 Cr** of unutilized equity to be deployed over 2–3 years across NBFC, HFC, and broking verticals, supporting scalable growth.
   *   **Dilution Concerns Addressed:** Management affirms financial services segment is well-capitalized; pending warrant conversions and prior fundraise de-risk near-term capital needs.

## D. Leverage & Liquidity
   *   **Strong Liquidity Position:** REL maintains robust liquidity enabling operational flexibility and strategic investments; RFL holds **₹500 Cr in cash** and operates unleveraged.
   *   **Planned Leverage Build:** RFL intends to gradually move toward industry-standard leverage over the next few years as new leadership stabilizes operations.
   *   **Credit Profile:** Investable **BBB-** rating from ICRA and CARE Edge supports funding access and credibility across 15 branches in 8 states.

---

# 4. Business & Segment Performance

## A. Key Figures
   *   **Insurance Total GWP:** **₹7,906 Cr** (+27% full premium basis)
   *   **Retail Health Growth:** **41% YoY** (proprietary channels)
   *   **Broking Revenue:** **₹91 Cr** (+12% YoY)
   *   **Client Debit Book:** **₹317 Cr** (+93% YoY)
   *   **AUM (Financial Services):** **₹241 Cr** (70% home loans, 30% LAP)
   * **Investment Book:** **₹10,246 Cr** (yield: 7.2–7.3%)
   *   **Client Assets Under Custody:** **₹42,642 Cr** (QoQ growth from ₹37,847 Cr)

## B. Insurance Segment Results
   *   **Retail Momentum Strong:** Care Health Insurance’s retail book expanded at a robust pace, capturing market share with **41% growth** and digital leadership—**96% of policies issued digitally** and rapid claims processing.
   *   **Performance Distortion Explained:** Elevated claims and combined ratios are transitional, driven by **1/n accounting and premium deferrals (₹1,400 Cr deferred)**; on a full premium basis, all key metrics show improvement.
   *   **Market Position Solid:** Company holds **9% share among private insurers** and **22% in SAHI segment**, with a **97% claims settlement ratio**, outperforming industry growth in key niches despite lower overall market share.
   *   **Cost Discipline Achieved:** EOM ratio improved by **150 bps**, remaining within regulatory limits, while management emphasizes **combined ratio** as the key performance benchmark.

## C. Broking & Financial Services
   *   **Broking Volume Surge:** Religare Broking delivered strong revenue growth and a near-doubling of client debit book, with **derivatives turnover at ₹9,782 Cr** and rising retail participation via SIPs and digital adoption.
   *   **Active Client Gap Identified:** Despite large client base, **only 14% of Demat holders are active traders**, below the **21% industry average**, highlighting a key productivity improvement opportunity.
   *   **Leadership & Capital Reinforcement:** New MD for broking and senior hires (ex-Bajaj, UTI) in place; **additional leadership appointments imminent**, with **₹900 Cr earmarked for financial services scaling**.
   *   **Strategic Demerger Clarity:** RFL to house broking, lending, and housing finance on a going-concern basis; REL retains full stake in Care Health Insurance, ensuring strategic focus post-split.

## D. Product Mix & AUM
   *   **AUM Expansion Underway:** Investment book surpassed **₹10,000 Cr** with **₹1,800 Cr growth** since March 2025, supported by capital infusion and strong retail credit tailwinds.
   *   **Affordable Housing in Focus:** Housing finance AUM growing at **20–22%**, led by **₹10 lakh average ticket size** loans, in a high-potential market with only **11% mortgage-to-GDP penetration**.
   *   **Retail Credit Tailwinds:** Sustained SIP inflows and digital adoption driving capital markets activity; insurance rebounded post-GST disruption, signaling durable demand recovery.

---

# 5. Regulatory & Legal Risks

## A. Governance & Promoter Status
   *   **Board Reconstitution:** Board strengthened with addition of **3 promoter nominees** and proposed induction of Dr. Anand Burman, Mr. Mohit Burman, and Mr. Aditya Chand Burman as Non-Executive, Non-Independent Directors, pending regulatory approvals.
   *   **New Director Nominee:** Mr. Jimeet Modi (SAMCO Group) proposed as Additional Director, Non-Executive and Non-Independent, subject to clearance.
   *   **Promoter Shareholding Below Threshold:** Look-through promoter ownership in CARE remains at **18%-19%**, below IRDAI’s **25% requirement** for classification as promoter, blocking structural moves like reverse merger.
   *   **Commitment Ambiguity:** Burman family’s stakes in other insurers raise questions about strategic intent; management affirms REL remains promoter but defers decisions to promoter group.

## B. Regulatory & Sector Developments
   *   **Positive Insurance Reforms:** Sector benefits from **100% FDI allowance**, **GST exemption on individual health/life policies**, and new labor code implementation.
   *   **Structural Hurdle:** Reverse merger not feasible under current IRDAI rules due to insufficient promoter holding; resolution contingent on promoter action or regulatory change.

## C. LVB FD Recovery & Litigation
   *   **LVB Matter Sub Judice:** Recovery efforts related to LVB fixed deposit remain ongoing in Delhi High Court; **DBS has replaced LVB** post-takeover, with no near-term resolution expected.
   *   **Recovery Strategy:** Company open to **out-of-court settlement or aggressive litigation**, pursuing full recovery of principal and interest; recovered funds to be shared with erstwhile lenders per agreement.
   *   **ESOP Dispute Ongoing:** ESOPs exceeding **2% of equity** granted to former CEO are partially exercised and under legal scrutiny; accounts written off, matter sub judice.
   *   **Legal Pragmatism:** General Counsel emphasizes that **"unless and until we see the color of the money, then there's no point in that cash"**, underscoring focus on actual recovery over theoretical calculations.

---

# 6. Guidance & Outlook

## A. Demerger Structure & Timeline
   *   **Strategic Separation Approved:** Boards of REL and RFL approved demerger into two independent, focused listed entities—RFL (financial services) and REL (retaining full ownership of CARE).
   *   **1:1 Share Distribution:** RFL will issue fully paid-up equity shares to REL shareholders on a **1:1 basis**, preserving ownership parity.
   *   **Targeted Listing in FY28:** RFL aims for stock exchange listing in **Q1 FY2028**, contingent on approvals and execution of a **15–18 month timeline** under Sections 230–232 of the Companies Act.
   *   **No Operational Disruption:** Transition expected to be seamless—**no impact on customers, employees, or regulatory registrations**.
   *   **Value Unlock via Focus:** Demerger enables **independent governance, capital structures, and growth mandates**, with four pillars: business focus, shareholder value, management alignment, and enhanced compliance.

## B. Future Capital & Restructuring Path
   *   **Capital Plans Post-Demerger:** RFL has **sufficient capital to restart operations**; incremental raises will be assessed after **18 months of post-demerger performance**.
   *   **Long-Term Restructuring Vision:** Current demerger is **first step** toward simplifying structure; future integration of insurance operations remains possible but unconfirmed.
   *   **No Reverse Merger Planned:** **CARE will not be reverse-merged into REL** at this stage—REL to operate as a single-asset holding company.
   *   **Promoter Commitment Emphasized:** Burman Group’s leadership brings **proven institution-building experience**, with decisions guided by **360-degree evaluation**, not conservatism.

## C. Business Restart & Investor Engagement
   *   **Restart Imminent, Timing Unclear:** Business restart expected **soon**, supported by resolved legacy issues and **regulatory cap removal**, though no specific disbursement timeline provided.
   *   **Investor Demand for Leadership Visibility:** Shareholders urged **Burman family** and **Anuj (Founder, CEO & MD)** to participate in future calls to articulate **long-term vision** and build confidence amid historical challenges.
   *   **Clean Balance Sheet:** All **legacy assets tied to demerged business written off**—future recoveries to be treated as upside.
   *   **New Leadership Mandate:** Incoming leaders to be **industry experts with entrepreneurial mindset**, focused on **multifold scaling** of respective businesses.